Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Melanoma

This is a clinical practice guideline for adult patients with completely resected cutaneous or mucosal melanoma, who are at a high risk for recurrence. The guideline examines the use of adjuvant systemic therapy for the prevention of recurrence in these patients. Molecular testing is discussed, and different recommendations are made based on the presence or absence of BRAF V600E or V600K mutations.